Journal
CURRENT HYPERTENSION REPORTS
Volume 13, Issue 2, Pages 129-135Publisher
SPRINGER
DOI: 10.1007/s11906-011-0180-4
Keywords
Renin-angiotensin system; RAS; Angiotensin II; Cardiovascular disease; Heart; ACE; Renin; Chymase; ACE2
Categories
Funding
- NHLBI NIH HHS [R01 HL091469, P01 HL069020-10, R01 HL067724-12, R42 HL079729-03, R01 HL067724, R42 HL079729, R01 HL102738-03, R01 HL102738, R01 HL091469-05, P01 HL069020] Funding Source: Medline
- NIA NIH HHS [R01 AG023039-09, R01 AG023039, P01 AG027211-05, P01 AG027211] Funding Source: Medline
Ask authors/readers for more resources
Despite ongoing medical advances, cardiovascular disease continues to be a leading health concern. The renin-angiotensin system (RAS) plays an important role in regulating cardiovascular function, and is, therefore, the subject of extensive study. Several drugs currently used to treat hypertension and heart failure are designed to target angiotensin II synthesis and function, but thus far, none have been able to completely block the effects of RAS signaling. This review discusses current and emerging approaches towards inhibiting cardiac RAS function in order to further improve cardiovascular disease outcomes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
